Showing results (231-240 of 270) with videos related to
Sort By:
Pageof 27
Breast (Edinburgh, Scotland)|May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.Eclinicalmedicine|January 7, 2026
Incidence of non-colorectal/endometrial malignancies in individuals with Lynch syndrome: a retrospective cohort studySilvia Negro, Francesco Celotto, Francesca Schiavi, et al.Critical Reviews in Oncology/Hematology|June 9, 2019
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relativesStefania Gori, Massimo Barberis, Maria Angela Bella, et al.NPJ Breast Cancer|February 5, 2025
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapyLuca Mastrantoni, Giovanna Garufi, Giulia Giordano, et al.Nature Medicine|January 21, 2025
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trialSherene Loi, Roberto Salgado, Giuseppe Curigliano, et al.Cancer Treatment Reviews|August 29, 2024
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical reviewAlberto Zambelli, Laura Cortesi, Mariangela Gaudio, et al.Journal of the National Cancer Institute|December 28, 2022
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, et al.Cancers|July 18, 2020
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast CancerGaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.Pageof 27